Latest Content

Rising cancer rates in young adults highlight the need for employer support, flexible work and whole-person health programs to improve outcomes.

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial.

Dr. McKenzie discusses gallbladder cancer risk factors, imaging signs and how surgery and lymph node evaluation impact outcomes.

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August.

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control.

Five years ago, I finished treatment and was determined to be no evidence of disease. Until my most recent CT scan, there’s been no sign of recurrence.

Black patients were underrepresented in ovarian cancer trials and had lower overall survival than White patients in a pooled analysis of 1,903 participants.

Retevmo improved event-free survival in stage 2 to 3A RET fusion-positive non-small cell lung cancer after curative therapy, per phase 3 data.

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions.

A three-time survivor shares why persistent symptoms, second opinions and mental health support matter after cervical cancer.

Overview of diagnosis, stage-based treatments, side effects and follow-up to help patients with cancer understand care choices and expectations.

Learn diagnosis, treatments, side effects and key questions to help guide shared decisions with your oncology team after stage 4 ccRCC diagnosis.

Charles Walker discusses living liver donation, survivorship challenges and why self-advocacy and awareness are vital for patients with liver cancer